Saturday, November 21, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
Top storiesBack PageHow to earnLeaderboard
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyGTA WeekHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsLeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundHolder perksRobinhood Chain launchesRobinhood Chain projectsList your projectPremium project pagesPartnersThe Chain WeeklyRobinhood Chain Daily
PaparazziPaparazzi InkPaparazzi Ink top writersOpinionLive coverageEvents calendarThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyTerms of serviceCorrectionsAccuracy recordRelease notesAdvertiseMedia kitNews APIContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 52

FDA Clears Labeling Update for Exelixis's COMETRIQ, No New Use Added

The FDA approved a labeling supplement for Exelixis's COMETRIQ (cabozantinib) on Nov. 19, 2026, refreshing the prescribing and patient package inserts. No new indication, safety or efficacy change came with it — this one is housekeeping for a drug already on the market.

By the Paparazzi desk November 20, 2026 · 10:48 AM · quantisnow.com · 0 views
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: quantisnow.com.
  • The source published it on Nov 20, 2026 at 10:48 AM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

Exelixis picked up an FDA approval for its cancer drug COMETRIQ on Nov. 19, 2026. The action covers supplement SUPPL-15 to New Drug Application 203756, the filing tied to cabozantinib. It touches only the patient package insert and the package insert labeling. The updated label itself isn't posted on the FDA's site yet.

Nothing in the filing signals a broader win. There's no new indication, no shift in safety or efficacy language described, which makes this a routine refresh of prescribing paperwork for an approved product. The capsule strengths listed on the application remain 20 mg and 80 mg (base).

Sponsored

Investors watching EXEL have seen this kind of headline before. Across 29 sessions following earlier Exelixis announcements, the stock closed higher 19 times and lower 10 times, with a median move of 2.1% in either direction. Those figures track timing only, and many forces move a stock in a single session.

Recent reaction points were all over the map. Shares rose 4.8% the session after Exelixis posted third-quarter 2026 results on Oct. 30, 2026, while they slipped 1.0% after the company said it would release those results on Oct. 29. On Aug. 19, 2026, a new price target from BMO Capital Markets as it initiated coverage preceded a 2.4% gain. Exelixis has traded publicly since 2000 and sits in the Health Care sector.

TopicsExelixis · COMETRIQ · cabozantinib · FDA · EXEL · NDA 203756 · BMO Capital Markets

Share

Source: quantisnow.com

Written by AI from verified reporting.

More stories

  • Health & science 02:39 UTC · 4 hours ago · abc.net.au · Caught by @nandahidayat · 3 views
    Rallies across Australia hit back at insurance rule change threatening homebirths
  • Health & science 22:50 UTC · 8 hours ago · nbcnews.com · Caught by @doni.putri23 · 1 view
    Federal panel favors HPV tests over Pap smears, adds self-collection option
  • Health & science 19:52 UTC · 11 hours ago · medicalxpress.com · Caught by @ajayy30 · 1 view
    Guinea Pig Ears Upend the Nobel-Winning Map of How We Hear
  • Health & science 19:50 UTC · 11 hours ago · phys.org · Caught by @ajayy30 · 0 views
    Lopsided galaxies are shaped from within, catalog of 606 suggests
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.